MedTrace Logo

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

NCT02389972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2017-09-11

No results posted yet for this study

Summary

The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.

Conditions

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG

Dasatinib

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-11
Primary Completion
2017-07-13
Completion
2017-07-13

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02389972 on ClinicalTrials.gov